15 completed, 5 terminated, 2 withdrawn, 1 recruiting. 24 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 15, Terminated 5, Withdrawn 2, Recruiting 1, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis Terfenadine, Standard First-line Disease-Modifying Therapy - Relapsing Remitting Multiple Sclerosis | Phase 2 | Recruiting | Chuan Qin | 100 | 2026-08-15 | 2026-09-18 |
| Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis PIPE-307 Dose A, PIPE-307 Dose B, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Janssen Research & Development, LLC | 182 | 2023-11-06 | 2026-09-25 |
| A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis placebo, orelabrutinib - Relapsing Remitting Multiple Sclerosis | Phase 2 | Unknown | Beijing InnoCare Pharma Tech Co., Ltd. | 160 | 2021-03-01 | 2023-04-21 |
| Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis CNM-Au8, Placebo - Relapsing Remitting Multiple Sclerosis, Optic Neuropathy | Phase 2 | Terminated | Clene Nanomedicine | 73 | 2018-11-23 | 2023-04-03 |
| An Extension of the TG1101-RMS201 Trial Ublituximab - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | TG Therapeutics, Inc. | 48 | 2017-06-01 | 2022-12-21 |
| Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis IL2, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 30 | 2016-06-13 | 2020-11-09 |
| Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) Plovamer acetate 0.5 milligram (mg), Copaxone 20 mg, Plovamer acetate 3 mg - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 255 | 2013-10-01 | 2016-05-11 |
| Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS) RHB-104 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | RedHill Biopharma Limited | 18 | 2013-06-01 | 2016-07-28 |
| Raltegravir (Isentress) Pilot Study in Relapsing Multiple Sclerosis Raltegravir - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Queen Mary University of London | 23 | 2013-04-01 | 2017-05-30 |
| Safety, Tolerability And Mechanism Of Action Of Boswellic Acids (BA) In Multiple Sclerosis (SABA) Boswellic acids (BOSWELAN) - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Universitätsklinikum Hamburg-Eppendorf | 29 | 2011-09-01 | 2020-02-25 |
| A Phase IIa Study of NT-KO-003 for Multiple Sclerosis NT-KO-003 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Neurotec Pharma | 99 | 2011-06-01 | 2014-03-18 |
| High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis Cyclophosphamide/Glatiramer acetate - Relapsing Remitting Multiple Sclerosis | Phase 2 | Withdrawn | Johns Hopkins University | 2010-11-01 | 2018-09-26 | |
| Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis BAF312 - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2010-08-30 | 2018-03-27 |
| Treatment Interruption of Natalizumab natalizumab, interferon beta 1-a, methylprednisolone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Biogen | 175 | 2010-03-01 | 2013-09-19 |
| A Study of Orally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Pleneva TM BGC20-0134, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Boston Scientific Corporation | 173 | 2009-11-01 | 2022-06-03 |
| Flupirtine as Oral Treatment in Multiple Sclerosis Flupirtine, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Charite University, Berlin, Germany | 30 | 2007-12-01 | 2018-03-20 |
| A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) Estriol, Placebo, Copaxone - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | University of California, Los Angeles | 158 | 2007-03-01 | 2016-06-16 |
| A Study for Patients With Relapsing Remitting Multiple Sclerosis dirucotide, placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 / Phase 3 | Completed | Eli Lilly and Company | 218 | 2006-11-01 | 2010-09-09 |
| BHT-3009 Immunotherapy in Relapsing Remitting Multiple Sclerosis BHT-3009 0.5 mg, BHT-3009 1.5 mg, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Completed | Bayhill Therapeutics | 252 | 2006-02-01 | 2008-02-11 |
| An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the Disease Laquinimod, Placebo - Relapsing Remitting Multiple Sclerosis | Phase 2 | Terminated | Teva Pharmaceutical Industries, Ltd. | 257 | 2005-12-07 | 2019-03-27 |
Showing 20 of 24. Sign in to see all of them.
Multiple Sclerosis, Relapsing-Remitting (24) · Multiple Sclerosis (6) · Demyelinating Diseases (2) · Autoimmune Diseases (1) · Camurati-Engelmann Syndrome (1) · Neuritis (1) · Optic Nerve Diseases (1)
Autoimmune Diseases of the Nervous System (24) · Demyelinating Autoimmune Diseases, CNS (24) · Immune System Diseases (24) · Nervous System Diseases (24) · Autoimmune Diseases (23) · Demyelinating Diseases (22) · Multiple Sclerosis (18) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cranial Nerve Diseases (1) · Eye Diseases (1) · Genetic Diseases, Inborn (1) · Musculoskeletal Diseases (1) · Neuromuscular Diseases (1)
Glatiramer Acetate (5) · Interferon beta-1a (2) · BHT 3009 (1) · Cyclophosphamide (1) · Estriol (1) · Estrogens (1) · Interleukin-2 (1) · MBP-8298 (1) · Methylprednisolone (1) · Mitoxantrone (1) · Natalizumab (1) · RNS60 (1) · Raltegravir Potassium (1) · Sugars (1) · Terfenadine (1)
Charite University, Berlin, Germany (2) · Teva Branded Pharmaceutical Products R&D, Inc. (2) · Assistance Publique - Hôpitaux de Paris (1) · Bayhill Therapeutics (1) · Beijing InnoCare Pharma Tech Co., Ltd. (1) · Biogen (1) · Boston Scientific Corporation (1) · Chuan Qin (1) · Clene Nanomedicine (1) · EMD Serono (1) · Eli Lilly and Company (1) · Janssen Research & Development, LLC (1) · Johns Hopkins University (1) · Neurotec Pharma (1) · Novartis Pharmaceuticals (1)
United States (10) · Germany (7) · Poland (6) · Spain (6) · Russia (5) · Canada (3) · Hungary (3) · Italy (3) · Ukraine (3) · United Kingdom (3) · Bulgaria (2) · China (2) · Czechia (2) · Finland (2) · France (2)
Anne Cross, M.D. (1) · Anthony Reder, M.D. (1) · Barbara Giesser, M.D. (1) · Christoph Heesen, MD (1) · Chuan Qin (1) · Corey Ford, M.D. (1) · Daniel Harrison, MD (1) · David Klatzmann (1) · Dean Wingerchuk, M.D. (1) · Dina Jacobs, M.D. (1) · Elliot Frohman, M.D. (1) · Frank Valone, MD (1) · Frauke Zipp, MD (1) · Fred Lublin, MD, PhD (1)
PMID 18398457, PMID 18572078, PMID 26049148, PMID 26621682, PMID 27380540, PMID 30873106, PMID 37245191, PMID 38648580
2004 (1), 2005 (1), 2009 (1), 2014 (1), R01NS051591 (1)